The Mayo Clinic is taking part in a massive data collection program aimed at unlocking the root causes of obesity and developing effective treatments.

The Minnesota-based health system is participating in a biobanking registry developed by Phenomix Sciences, a biotech company developed by Mayo Clinic researchers and launched out of the American Medical Association’s Health2047 subsidiary in 2021, and will be participating in an outcomes study aimed at monitoring phenotypes in patients being treated for obesity.